Phonenix, Arizona Clinical Trials

A listing of Phonenix, Arizona clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
qa123

sdf

Test Site 3
 (0.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Smoke Testing v6.14.1  

Testing

Test Site 3
 (0.2 away)
  • 0 views
  • 14 Jun, 2024
  • +5 other locations
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

flortaucipir
florbetapir
alzheimer's disease
positron emission tomography
mini-mental state examination
Banner Alzheimer's Institute
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +85 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

hemarthrosis
haemophilia a
antihemophilic factor
fitusiran
hemophilia
Investigational Site Number 8400009
 (5.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
manual trial test  

manual trial test overview

Test Site 3
 (0.2 away)
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

aphasia
progranulin
pick's disease
dementia
Dignity Health
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

headache
treatment regimen
preventive medication
migraine
lasmiditan
21st Century Neurology
 (0.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
An Efficacy and Safety Study of Ravulizumab in ALS Participants

The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

vaccination
edaravone
riluzole
ravulizumab
Neuromuscular Research Center and Clinic
 (9.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Multicenter Clinical Trial of a Phakic Implantable Collamer Lens (ICL)

This objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the EVO/EVO+ Visian Implantable Collamer Lens (ICL) in study participants who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be evaluated when 300 primary eyes complete 6 …

astigmatism
severe myopia
myopia
Barnett Dulaney Perkins
 (0.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +13 other locations
Infigratinib in Recurrent Glioblastoma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed …

red blood cell transfusion
peripheral neuropathy
infigratinib
FGFR3
screening procedures
St. Joseph's Hospital and Medical Center
 (4.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations